# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Bill Maughan maintains Moderna (NASDAQ:MRNA) with a Hold and raises the price target from $91 to $...
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $125 to $135.
Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $142 to ...
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism ...
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just repo...